| Value | ₹57.74 Cr |
|---|
BSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,865.00
- Market cap
- ₹35,381 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.0×Sector 48.7×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Other legal & regulatory announcements
All →Waaree Energies Legal & Regulatory
Waaree Energies disclosed GPCB's January 2026 closure direction for its Degam solar cell plant, since revoked and extended. Interim compensation and bank guarantees total ₹0.17 Crore.
- Value
- ₹0.17 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital Ltd received a favourable income tax order for AY 2023-24, granting relief of ₹40.03 crore against a total disputed amount of ₹42.90 crore.
- Value
- ₹40.03 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital's appeal against an Income Tax order for A.Y. 2023-24 was partly allowed, granting the company relief of ₹40.03 Crore.
- Value
- ₹42.90 Cr
Max Healthcare Institute Legal & Regulatory
Max Healthcare informed the Exchange that the NCLT hearing regarding petitions against its subsidiary, Kalinga Hospital Ltd., was adjourned to October 30, 2026.
Bank of Baroda Legal & Regulatory
Bank of Baroda clarified media-reported interim applications filed by Dr. BR Shetty in the Bombay High Court. The bank says it has not been served and calls the allegations untested.
Canara Bank Legal & Regulatory
Canara Bank disclosed an RBI penalty of Rs. 7,30,000 over ATM cashout at 73 ATMs in Karnataka and Tamil Nadu. The penalty is the only quantified impact.
- Value
- ₹0.07 Cr